Sopharma pharmaceuticalsSopharma licensed pharmaceuticalsSopharma pharmaceuticals no MA
Sopharma ointmentsSopharma food supplementsSopharma medical devices


For prolonged treatment of bronchospastic syndrome

INN: Clenbuterol

Код АТХ: R03CC 13


One tablet contains 0.02 mg clenbuterol hydrochloride.


For prolonged treatment of bronchospastic syndrome in mild and moderate atopic and non-atopic bronchial asthma; strain-induced bronchospasm; in the complex therapy of chronic spastic bronchitis and COPD.

Dosage and administration:

Adults: 0,02 mg orally, morning and evening; Maintenance dose – 0,01 mg 2 times daily. In more serious conditions, 0,04 mg, 2 times daily (morning and evening) should be administered in the first days. The dose should be reduced upon condition improving. In children: 6-12 years –1/2 tablet 2 times daily. Over 12 years –1/2 tablet 2-3 times daily or 1 tablet 2 times daily.


Hypersensitivity to the product; thyrotoxicosis; digitalis intoxication, tachycardia, tachyarrhythmia, hyperthrophic obstructive cardiomyopathy; first trimester of pregnancy.

Drug interactions:

Beta-blockers antagonize Clenbuterol effects. In concomitant administration with antidiabetics, their dose should be increased due to glycogenolysis stimulation by Clenbuterol. Co-administration with cardiac glycosides, MAO-inhibitors and theophylline may cause heart rhythm disorders.

The effect of Clenbuterol is potentiated by tricyclic antidepressants, some antihistamines and levothyroxin and reduced by some antihypertensive products (guanethidine). Halothane and other halogenated hydrocarbon anesthetics and cyclopropane sensitize myocardium and may potentiate the arrhythmogenic effect of в2- sympathomimetics.

Adverse reactions:

Insomnia, headache, hyperkinesias, psychic disorders, reddening, sweating, tremor and anxiety, excitability, dizziness; the patients with Parkinson’s syndrome may feel increase of tremor and muscle rigidity; palpitations, tachycardia, reduction or, rarely, rise of blood pressure; urine retention; paradoxical bronchospasm which requires immediate discontinuation of therapy. In patients with diabetes mellitus, hyperglycaemia may develop. The manifestation of such adverse reactions requires dose reduction without need of therapy termination, because they fade within 1-2 weeks after therapy initiation. In prolonged administration, tachyphyllaxis to Clenbuterol may be observed, but sensitivity is restored after discontinuation of therapy.


50 tablets of 0,02 mg.


On doctor’s prescription.

Serving from:
Las Vegas, NV 89135
Sofia, Bulgaria 1125

Humanofort anti-aging

Oils and aromatics

MMB 750 prebiotic


Hempcell rejuvenation
Agile shopping system Twitter page Tumblr page Facebook page

Copyright © 2016-2018 BPG Ltd/Biogenic Stimulants, Inc. All rights reserved.